Clinical Trials Sponsored by Eucure (Beijing) Biopharma Co., Ltd

Total 989 results

Eucure (Beijing) Biopharma Co., Ltd

Recruiting

A Study to Evaluate the Combination of YH003, YH001 and Pembrolizumab in Subjects With Advanced Solid Tumors

Solid Tumor

Australia
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

A Study to Assess YH002 in Combination With YH001 in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

China, Australia
Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Evaluate YH003 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Evaluate YH001 in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

China
Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Evaluate YH003 in Combination With Toripalimab (Anti-PD-1 mAb) in Subjects With Advanced Solid Tumors

Advanced Solid Tumors

Australia
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

Study of YH004 (4-1BB Agonist Antibody) in Advanced Solid Tumors And Relapsed Or Refractory Non-Hodgkin Lymphoma

Advanced Solid Tumors | Relapsed Or Refractory Non-Hodgkin Lymphoma

China
Eucure (Beijing) Biopharma Co., Ltd

Recruiting

A Study to Assess YH003 in Combination With Pebolizumab and Albumin Paclitaxel Injection in Subjects With Unresectable/Metastatic Mucosal Melanoma

Mucosal Melanoma

China
Eucure (Beijing) Biopharma Co., Ltd

Completed

Study of YH004 (4-1BB Agonist Antibody) in Advanced or Metastatic Malignancy

Cancer

Australia
Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Assess YH001 in Combination With Toripalimab Injection in Subjects With Advanced Solid Tumors

Advanced Solid Tumor

Australia
Eucure (Beijing) Biopharma Co., Ltd

Active, not recruiting

A Study to Assess YH003 in Combination With Toripalimab(Anti-PD-1 mAb) Injection in Patients With Cancers

Melanoma | Pancreatic Ductal Adenocarcinoma

United States, Australia
Eucure (Beijing) Biopharma Co., Ltd

Withdrawn

A Study to Evaluate YH001 in Combination With Toripalimab in Subjects With Advanced NSCLC and HCC (YH001)

HCC | NSCLC Stage IV | NSCLC Stage IIIB

China, Australia, Taiwan, Armenia, Austria
Eucure (Beijing) Biopharma Co., Ltd

Completed

A Study to Evaluate the Safety, Tolerability and How YH002 Enters, Moves Through and Exits the Body in Subjects With Advanced Solid Malignancies

Advanced Solid Malignancies

Australia
Beijing Kejing Biotechnology Co., Ltd.
Beijing Kejing Biotechnology Corp.

Withdrawn

An Exploratory Clinical Study to Evaluate the Safety and Efficacy of NK Cells (Combined With Standard Therapy) in the Treatment of Solid Tumor Patients (CCT-ANK-11)

Solid Tumors (Pancreatic Cancer, Esophageal Cancer, Gastric Cancer, Cholangiocarcinoma, Lung Cancer and Ovarian Cancer)

China
WestVac Biopharma Co., Ltd.
WestVac Biopharma (Guangzhou) Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate the Efficacy, Safety and Immunogenicity of Booster Vaccination With Recombinant COVID-19 (XBB) Trimer Protein Vaccine (Sf9 Cell)

COVID-19

China
Newsoara Biopharma Co., Ltd.

Not yet recruiting

HY1272 in Patients With Locally Advanced or Metastatic Solid Tumors or Locally Advanced or Metastatic EGFRm+ NSCLC

NSCLC Stage IV
Ausper Biopharma Co., Ltd.

Recruiting

A Study to Evaluate the Safety and Efficacy of AHB-137 in Healthy Participants and Chronic Hepatitis B Patients

Hepatitis B, Chronic

China
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Clinical Trial of Recombinant COVID-19 Bivalent (XBB+Prototype) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
Newsoara Biopharma Co., Ltd.

Recruiting

Safety, Tolerance and Pharmacokinetics of THR-1442 in Chinese Healthy Subjects

T2DM (Type 2 Diabetes Mellitus)

China
Genor Biopharma Co., Ltd.

Recruiting

A Phase Ib Study of GB491 Plus Letrozole in Patients With Advanced Breast Cancer

Advanced Breast Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

GB491 Combined With Fulvestrant for HR+ HER2- Locally Advanced or Metastatic Breast Cancer

Locally Advanced or Metastatic Breast Cancer

China
Haihe Biopharma Co., Ltd.

Recruiting

Evaluate the Safety and Clinical Activity of HH2853

Advanced Solid Tumor | Non-Hodgkin's Lymphoma, Relapsed | Non-Hodgkin's Lymphoma Refractory

United States, China
Genor Biopharma Co., Ltd.

Recruiting

A Study in Recurrent or Metastatic Cervical Cancer Patients With PD-L1 Positive

Cervical Cancer

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of B-cell Non-Hodgkin's Lymphoma(GB226)

B-cell Non-Hodgkin's Lymphoma

China
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Elapsed/Metastatic/Unresectable Alveolar Soft Part Sarcoma(GB226)

Alveolar Soft Part Sarcoma

China
Genor Biopharma Co., Ltd.

Recruiting

Phase I Clinical Trial in Chinese Patients of Advanced and (or) Recurrent Solid Tumor/Lymphoma (GB226)

Lymphoma | Advanced Solid Tumor | Recurrent Solid Tumor | Recurrent Lymphocyte Depleted Classical Hodgkin Lymphoma

China
TJ Biopharma Co., Ltd.

Completed

A Study to Evaluate the Safety and Tolerability, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of TJ011133 as Monotherapy and in Combination With Azacitidine (AZA) in Patients With Acute Myeloid Leukemia (AML) or Myelodysplastic Syndrome (MDS)

Acute Myeloid Leukemia (AML) | Myelodysplastic Syndromes(MDS)

China
TJ Biopharma Co., Ltd.

Withdrawn

Clinical Trial of TJ271 Injection Combined With Pembrolizumab in the Treatment of Advanced Solid Tumors

First-line Non-small-cell Lung Cancer | First-line Urothelial Carcinoma | Second-line Urothelial Carcinoma | Second-line Melanoma

China
Advagene Biopharma Co. Ltd.

Completed

Evaluating Safety, Tolerability, and Potential Efficacy of Intranasal AD17002 in Adults With Mild to Moderate COVID-19

COVID-19

Taiwan
Haihe Biopharma Co., Ltd.

Terminated

A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of HH2710 in Patient With Advanced Tumors

Melanoma | Erdheim-Chester Disease | Non-Small-Cell Lung Cancer | Advanced Tumors | Other RAS/RAF/MEK/ERK Mutated Tumors

United States, China
Haihe Biopharma Co., Ltd.

Terminated

First in Human Study to Evaluate the Safety, Tolerability of HH30134 in Advanced Solid Tumors

Advanced Solid Tumors

China, Australia
Haihe Biopharma Co., Ltd.

Completed

Single Dose Glumetinib in Healthy Chinese Male Subjects

Healthy Volunteers

China
Newsoara Biopharma Co., Ltd.

Completed

Study to Evaluate LB1148 for Return of Gastrointestinal Function, Decrease Post-Operative Ileus

Ileus

China
Genor Biopharma Co., Ltd.

Unknown

Phase I Clinical Study of GB222 to Evaluate the Safety, Tolerability and PK Profiles.

Brain Tumor

China
Genor Biopharma Co., Ltd.

Unknown

Phase Ⅰ Clinical Study Protocol of GB223 Monoclonal Antibody Injection

Bone Tumor

China
Centaurus Biopharma Co., Ltd.

Unknown

Study of Safety,Efficacy and Pharmacokinetics of CT-1530 in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia

Chronic Lymphocytic Leukemia | Waldenstrom's Macroglobulinemia | Diffuse Large B Cell Lymphoma | Relapsed or Refractory B Cell Non-Hodgkin Lymphoma | Mantle Zone Lymphoma Refractory/Recurrent | Follicle Centre Lymphoma Diffuse

China
Haihe Biopharma Co., Ltd.

Unknown

Study to Evaluate the Safety, Tolerability, Preliminary Efficacy and Pharmacokinetics of Simmitecan Monotherapy and Combination in Patients With Advanced Solid Tumors

Advanced Solid Tumor | Advanced/Metastatic Colorectal Cancer

China
Centaurus Biopharma Co., Ltd.

Unknown

Study of Safety, Efficacy and Pharmacokinetics of CT-707 in Patients With ALK-positive Non-small Cell Lung Cancer

Non-small Cell Lung Cancer

China
HanAll BioPharma Co., Ltd.

Unknown

Bioequivalence Study (Candesartan 16 mg and Amlodipine 10 mg)

Hypertension
HanAll BioPharma Co., Ltd.

Completed

Phase 2 Study of HL-009 Liposomal Gel to Treat Mild to Moderate Atopic Dermatitis

Mild to Moderate Atopic Dermatitis

United States
HanAll BioPharma Co., Ltd.

Completed

Safety, Pharmacokinetics and Pharmacodynamics Study of HL-032 in Healthy Male Volunteers (HL-032)

Growth Hormone Deficiency

Korea, Republic of
JKT Biopharma Co., Ltd.

Not yet recruiting

SHEN211 Tablets for the Treatment of Mild and Moderate Novel Corona Virus Infections (COVID-19)

COVID-19

China
TJ Biopharma Co., Ltd.

Recruiting

Study of Felzartamab in Healthy Adult Subjects

Healthy

China
JKT Biopharma Co., Ltd.

Recruiting

The Safety, Tolerability, Pharmacokinetics and Food Effects of SHEN211 Tablet in Healthy Subjects

Phase 1

China
WestVac Biopharma Co., Ltd.

Not yet recruiting

A Phase Ⅲ Clinical Trial of Recombinant COVID-19 Trivalent (XBB+BA.5+Delta) Protein Vaccine (Sf9 Cell) in Booster Vaccination

COVID-19
TJ Biopharma Co., Ltd.

Recruiting

A Phase 3 Clinical Study to Evaluate Lemzoparlimab for Injection in Combination With Azacitidine (AZA) Versus AZA Monotherapy in Treatment-naïve Patients With Higher-risk Myelodysplastic Syndrome (MDS)

Myelodysplastic Syndromes(MDS)

China
Boryung Biopharma Co., Ltd.

Not yet recruiting

To Evaluate the Immunogenicity and Safety of Inactivated Hepatitis A Vaccine in Healthy Children Aged From 24mons-15yrs

Hepatitis A | Hep A

Korea, Republic of, Thailand
Genor Biopharma Co., Ltd.

Recruiting

A Safety, Tolerability, Pharmacokinetics and Efficacy Study of GB261 in B-Cell NHL and CLL.

CLL | B Cell NHL

Australia
Haihe Biopharma Co., Ltd.

Recruiting

Assessment of Anti-tumor and Safety in Glumetinib in Patients With c-MET-positive Non-Small Cell Lung Cancer

C-Met Exon 14 Mutation

China, Japan, United States
Genor Biopharma Co., Ltd.

Recruiting

Clinical Trial in Chinese Patients of Relapsed and Refractory Peripheral T Cell Lymphoma (GB226)

Peripheral T Cell Lymphoma

China
WestVac Biopharma Co., Ltd.

Completed

A Clinical Trial of Immuno-bridging Between Different Manufacture Scales of Recombinant COVID-19 Vaccine (Sf9 Cell)

COVID-19 | SARS-CoV-2 Pneumonia

China

3

Subscribe